| Crohn Disease
Avsola vs Rinvoq
Side-by-side clinical, coverage, and cost comparison for crohn disease.Deep comparison between: Avsola vs Rinvoq with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRinvoq has a higher rate of injection site reactions vs Avsola based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Rinvoq but not Avsola, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Avsola
Rinvoq
At A Glance
IV infusion
Every 6-8 weeks
TNF-alpha inhibitor
Oral
Once daily or twice daily (pediatric oral solution)
JAK inhibitor
Indications
- Crohn Disease
- Ulcerative Colitis
- Rheumatoid Arthritis
- Arthritis, Psoriatic
- Psoriasis
- Rheumatoid Arthritis
- Arthritis, Psoriatic
- Dermatitis, Atopic
- Ulcerative Colitis
- Crohn Disease
- Ankylosing spondylitis
- Non-Radiographic Axial Spondyloarthritis
- Juvenile polyarthritis
- Giant Cell Arteritis
Dosing
Crohn Disease, Ulcerative Colitis, Arthritis, Psoriatic, Psoriasis 5 mg/kg IV induction at weeks 0, 2, and 6, followed by 5 mg/kg every 8 weeks maintenance.
Rheumatoid Arthritis 3 mg/kg IV induction at weeks 0, 2, and 6, followed by 3 mg/kg every 8 weeks maintenance, in combination with methotrexate.
Ankylosing Spondylitis 5 mg/kg IV induction at weeks 0, 2, and 6, followed by 5 mg/kg every 6 weeks maintenance.
Rheumatoid Arthritis 15 mg orally once daily
Arthritis, Psoriatic - Adults 15 mg orally once daily
Arthritis, Psoriatic - Pediatric 2 to <18 years Dosing based on weight: 10-<20 kg: 3 mg oral solution twice daily; 20-<30 kg: 4 mg oral solution twice daily; >=30 kg: 6 mg oral solution twice daily or 15 mg tablet once daily
Dermatitis, Atopic - Adults <65 years 15 mg orally once daily; may increase to 30 mg once daily if inadequate response
Dermatitis, Atopic - Adults >=65 years 15 mg orally once daily
Ulcerative Colitis - Induction 45 mg orally once daily for 8 weeks
Ulcerative Colitis - Maintenance 15 mg orally once daily; may use 30 mg once daily for refractory, severe, or extensive disease
Crohn Disease - Induction 45 mg orally once daily for 12 weeks
Crohn Disease - Maintenance 15 mg orally once daily; may use 30 mg once daily for refractory, severe, or extensive disease
Ankylosing spondylitis 15 mg orally once daily
Non-Radiographic Axial Spondyloarthritis 15 mg orally once daily
Juvenile polyarthritis Dosing based on weight: 10-<20 kg: 3 mg oral solution twice daily; 20-<30 kg: 4 mg oral solution twice daily; >=30 kg: 6 mg oral solution twice daily or 15 mg tablet once daily
Giant Cell Arteritis 15 mg orally once daily in combination with tapering corticosteroids; may continue as monotherapy after corticosteroid discontinuation
Contraindications
- Doses >5 mg/kg in patients with moderate or severe heart failure
- Previous severe hypersensitivity reaction to infliximab products, any inactive ingredient of AVSOLA, or murine proteins
- Known hypersensitivity to upadacitinib or any excipients
Adverse Reactions
Most common (>10%) Infections (upper respiratory, sinusitis, pharyngitis), infusion-related reactions, headache, abdominal pain
Serious Pneumonia, cellulitis, abscess, skin ulceration, sepsis, bacterial infection, lymphoma, hepatotoxicity
Postmarketing Neutropenia, agranulocytosis, interstitial lung disease, Stevens-Johnson Syndrome, toxic epidermal necrolysis, acute liver failure, anaphylactic shock, cerebrovascular accidents, myocardial ischemia
Most common (>=3%) - Rheumatoid Arthritis Upper respiratory tract infection, nausea, cough, pyrexia
Most common (>=3%) - Atopic Dermatitis Upper respiratory tract infection, acne, herpes simplex, headache, increased blood creatine phosphokinase, cough, hypersensitivity, folliculitis, nausea, abdominal pain
Most common (>=3%) - Ulcerative Colitis Induction Upper respiratory tract infection, acne, increased blood creatine phosphokinase, neutropenia, rash, elevated liver enzymes, lymphopenia
Most common (>=3%) - Ulcerative Colitis Maintenance Upper respiratory tract infection, increased blood creatine phosphokinase, pyrexia, neutropenia, elevated liver enzymes, rash, herpes zoster, folliculitis, hypercholesterolemia, influenza, herpes simplex
Most common (>=3%) - Crohn Disease Induction Upper respiratory tract infection, anemia, acne, pyrexia, increased blood creatine phosphokinase, influenza, herpes simplex
Most common (>=3%) - Crohn Disease Maintenance Upper respiratory tract infection, pyrexia, herpes zoster, headache, acne, gastroenteritis, fatigue, increased blood creatine phosphokinase
Most common (>=5%) - Giant Cell Arteritis Upper respiratory tract infection, headache, fatigue, peripheral edema, cough, anemia, rash, herpes zoster, nausea
Serious Serious infections, opportunistic infections, tuberculosis, malignancies, major adverse cardiovascular events, thrombosis, gastrointestinal perforations, hypersensitivity reactions, eczema herpeticum
Pharmacology
TNF-alpha inhibitor; chimeric IgG1kappa monoclonal antibody that neutralizes TNFalpha by binding with high affinity to the soluble and transmembrane forms of TNFalpha, inhibiting binding of TNFalpha with its receptors.
Upadacitinib is a JAK inhibitor that modulates intracellular signaling by preventing JAK-mediated phosphorylation and activation of STATs, thereby influencing immune cell function and hematopoiesis.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Avsola
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
Rinvoq
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (12/12) · Qty limit (11/12)
UnitedHealthcare
Avsola
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Rinvoq
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (8/8) · Qty limit (8/8)
Humana
Avsola
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Rinvoq
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Avsola.
Cost estimate not availableCo-Pay Relief Rheumatoid Arthritis Fund
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Final cost depends on formulary coverage
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AvsolaView full Avsola profile
RinvoqView full Rinvoq profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.